Stamford, US Aug 22, 2025 (Issuewire.com) - Harrison Global Holdings Inc., formerly BloomZ Inc., has signed a strategic international partnership with Biotree Co., Ltd., a Korean biotech pioneer developing the worlds first natural product-based drug for metabolic syndrome.
Why This Matters to Investors
- Biotrees PH-100 has completed Phase 1 trials in the U.S. and Phase 2A trials in Korea, showing strong results in reducing inflammation and improving cardiovascular health.
- The drug is expected to receive conditional approval by mid-2026, opening up prescription-only revenue streams.
- Biotree is the first Korean firm to extract Seapolynol from Gamtae seaweedused in health foods, cosmetics, and pharmaceuticals.
- Harrison Global will help expand Biotrees reach into the U.S., Japan, China, and broader Asia through joint ventures, licensing, and localized development.
Strategic Synergy
This partnership blends Harrisons entertainment and youth engagement expertise with Biotrees biotech innovation, creating a hybrid growth engine across lifestyle, wellness, and media sectors.
Executive Insight
"Were thrilled to contribute to global health by supporting Biotrees breakthrough treatment," said Ryoshin Nakade, Co-CEO of Harrison Global. "This partnership reflects our commitment to innovation and international expansion."
Enrique Vargas
More On Ournewsnation ::
- zkLink Launches P2P AI Agent Trading Network Initiative, Aims to Power the Machine-Driven Financial Layer
- Peter Paul Hennis, AGNP: A Dedicated Nurse Practitioner Making Strides in Rheumatology Care in Arizona
- Sheldon Burnett Calls for Greater Awareness Around Supply Chain Transparency and Global Resilience
- QRFunnels Marks World Cleanup Day with Free Digital Business Card Giveaway
- Imagen Network (IMAGE) Strengthens User Data Ownership with AI-Driven Decentralization
(845) 288-0020
Source :Harrison Global Holdings
This article was originally published by IssueWire. Read the original article here.
13 hour's ago
13 hour's ago